ClinicalTrials.gg
CompletedNCT01516879DESCARTESUpdated Jul 22, 2022Results posted

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

A Phase 3 interventional study of Evolocumab and Placebo in Hypercholesterolemia, sponsored by Amgen. Completed at 96 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
905
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
8th of 36
905 · median 308
Started
2012
with 3 others
Phase 3
22 of 36
none open now
Registered
5th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 4 that started in 2012, is one of 22 in phase 3, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.

Read the detailed description

Eligible participants with screening central laboratory low-density lipoprotein cholesterol (LDL-C) values ≥ 75 mg/dL (1.9 mmol/L) were instructed to follow National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP) Therapeutic Lifestyle Changes (TLC) diet and were assigned to 1 of the following 4 background lipid-lowering therapies for a 4-week stabilization period based upon their screening LDL-C and its distance from the individual's required goal as stipulated by their NCEP ATP III risk category:

  1. no drug therapy required - diet alone
  2. low dose drug therapy required - diet plus atorvastatin 10 mg orally (PO) once daily (QD)
  3. high dose drug therapy required - diet plus atorvastatin 80 mg PO QD
  4. maximal drug therapy required - diet plus atorvastatin 80 mg PO QD plus ezetimibe 10 mg PO QD.

If the participant met entry criteria at the end of the lipid stabilization period they were randomized 2:1 to receive evolocumab 420 mg or placebo subcutaneously once a month for 52 weeks in addition to their background therapy.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Cholesterol
  • High Cholesterol
  • Elevated Cholesterol
  • Raised Cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided .
  • Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:

    • \< 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk equivalent
    • \< 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent
    • OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO QD and ezetimibe 10 mg PO QD
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • (NYHA) II-IV heart failure, or last known \< 30%
  • Uncontrolled cardiac arrhythmia
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes
  • Uncontrolled hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
905 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.

    Biological: Evolocumab · Drug: Atorvastatin · Drug: Ezetimibe · Other: Diet Only

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.

    Biological: Placebo · Drug: Atorvastatin · Drug: Ezetimibe · Other: Diet Only

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection once a month

    Also known as: AMG 145, Repatha

  • BiologicalPlacebo

    Administered by subcutaneous injection once a month

  • Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.

  • Background lipid lowering therapy: ezetimibe 10 mg orally once a day

  • OtherDiet Only

    Diet only, no lipid lowering background drug given

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 52

    Cholesterol was measured by means of ultracentrifugation.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 52

    Cholesterol was measured by means of ultracentrifugation.

    Time frame: Baseline and Week 52

  2. Percentage of Participants With an LDL-C Response at Week 52

    An LDL-C response is defined as LDL-C level \< 70 mg/dL (1.8 mmol/L) at Week 52.

    Time frame: Week 52

  3. Percent Change From Baseline in LDL-C at Week 12

    Cholesterol was measured by means of ultracentrifugation.

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Total Cholesterol at Week 12

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline in Total Cholesterol at Week 52

    Time frame: Baseline and Week 52

  6. Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52

    Time frame: Baseline and Week 52

  7. Percent Change From Baseline in Apolipoprotein B at Week 52

    Time frame: Baseline and Week 52

  8. Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52

    Time frame: Baseline and Week 52

  9. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52

    Time frame: Baseline and Week 52

  10. Percent Change From Baseline in Lipoprotein(a) at Week 52

    Time frame: Baseline and Week 52

  11. Percent Change From Baseline in Triglycerides at Week 52

    Time frame: Baseline and Week 52

  12. Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52

    Time frame: Baseline and Week 52

  13. Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52

    Cholesterol was measured by means of ultracentrifugation.

    Time frame: Baseline and Week 52

  14. Percent Change From Week 12 to Week 52 in LDL-C

    Cholesterol was measured by means of ultracentrifugation.

    Time frame: Week 12 and Week 52

07

Results

Posted Sep 29, 2015

Participant flow

Adults with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 75 mg/dL and triglycerides ≤ 400 mg/dL were eligible. The first patient enrolled on 5 January 2012 and the last patient enrolled on 12 October 2012. All patients were counseled on the National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes diet.

Participant flow — Overall Study
MilestonePlaceboEvolocumab
Started303602
Received treatment302599
Completed287568
Not completed1634
Withdrew: Withdrawal by subject911
Withdrew: Death02
Withdrew: Lost to follow-up211
Withdrew: Other510

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at Week 52

Cholesterol was measured by means of ultracentrifugation.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in LDL-C at Week 526.83 ± 1.75-50.14 ± 1.24
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -56.97 · 95% CI -61.08 to -52.85Treatment difference using placebo as the reference.
SecondaryChange From Baseline in LDL-C at Week 52

Cholesterol was measured by means of ultracentrifugation.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 52
mg/dLPlaceboEvolocumab
Change From Baseline in LDL-C at Week 525.1 ± 1.9-52.7 ± 1.4
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -57.8 · 95% CI -62.3 to -53.3Treatment difference using placebo as the reference.
SecondaryPercentage of Participants With an LDL-C Response at Week 52

An LDL-C response is defined as LDL-C level \< 70 mg/dL (1.8 mmol/L) at Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With an LDL-C Response at Week 52
percentage of participantsPlaceboEvolocumab
Percentage of Participants With an LDL-C Response at Week 526.4 (4.1 to 10.1)82.3 (78.8 to 85.3)
Statistical analysis
  • Placebo vs Evolocumab · Cochran-Mantel-Haenszel · p = <0.001 · Treatment difference: 75.8 · 95% CI 70.8 to 79.7Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in LDL-C at Week 12

Cholesterol was measured by means of ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 12
percent changePlaceboEvolocumab
Percent Change From Baseline in LDL-C at Week 123.17 ± 1.31-54.35 ± 0.96
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -57.51 · 95% CI -60.57 to -54.45Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Total Cholesterol at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 12
percent changePlaceboEvolocumab
Percent Change From Baseline in Total Cholesterol at Week 122.85 ± 0.87-32.30 ± 0.63
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -35.15 · 95% CI -37.19 to -33.11Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Total Cholesterol at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Total Cholesterol at Week 525.26 ± 1.16-28.18 ± 0.84
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -33.45 · 95% CI -36.21 to -30.68Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 528.44 ± 1.68-41.82 ± 1.21
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -50.27 · 95% CI -54.25 to -46.28Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Apolipoprotein B at Week 522.94 ± 1.41-41.26 ± 1.02
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -44.21 · 95% CI -47.56 to -40.85Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 526.47 ± 1.37-30.67 ± 0.99
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -37.14 · 95% CI -40.41 to -33.87Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 524.46 ± 1.50-41.75 ± 1.09
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -46.21 · 95% CI -49.79 to -42.63Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Lipoprotein(a) at Week 52-5.37 ± 1.62-27.72 ± 1.19
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -22.35 · 95% CI -26.15 to -18.55Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Triglycerides at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Triglycerides at Week 528.99 ± 2.39-2.55 ± 1.72
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -11.54 · 95% CI -17.21 to -5.86Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 520.35 ± 0.905.77 ± 0.65
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: 5.42 · 95% CI 3.28 to 7.56Treatment difference using placebo as the reference.
SecondaryPercent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52

Cholesterol was measured by means of ultracentrifugation.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52
percent changePlaceboEvolocumab
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 5231.89 ± 4.692.74 ± 3.36
Statistical analysis
  • Placebo vs Evolocumab · Repeated measures linear effects model · p = <0.001 · Ls mean treatment difference: -29.15 · 95% CI -40.23 to -18.08Treatment difference using placebo as the reference.
SecondaryPercent Change From Week 12 to Week 52 in LDL-C

Cholesterol was measured by means of ultracentrifugation.

Time frame:
Week 12 and Week 52
Reported as:
Least squares mean · percent change
Percent Change From Week 12 to Week 52 in LDL-C
percent changePlaceboEvolocumab
Percent Change From Week 12 to Week 52 in LDL-C2.57 ± 1.562.44 ± 1.14
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.94 · Ls mean treatment difference: -0.14 · 95% CI -3.76 to 3.48Treatment difference using placebo as the reference.

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—13/302 (4.3%)76/302 (25.2%)
Evolocumab—33/599 (5.5%)177/599 (29.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPlaceboEvolocumab
Angina pectorisCardiac disorders2/3022/599
PalpitationsCardiac disorders0/3022/599
Ventricular extrasystolesCardiac disorders0/3022/599
Vertigo positionalEar and labyrinth disorders0/3022/599
Back painMusculoskeletal and connective tissue disorders0/3022/599
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3022/599
Atrial fibrillationCardiac disorders1/3020/599
Sinus bradycardiaCardiac disorders1/3020/599
Chest painGeneral disorders1/3020/599
Joint injuryInjury, poisoning and procedural complications1/3020/599
Most frequent other events
Most frequent other events
EventPlaceboEvolocumab
NasopharyngitisInfections and infestations29/30263/599
Upper respiratory tract infectionInfections and infestations19/30256/599
InfluenzaInfections and infestations19/30245/599
Back painMusculoskeletal and connective tissue disorders17/30236/599

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEvolocumabTotal
Mean56.6 ± 10.355.9 ± 10.956.1 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumabTotal
Female162312474
Male141290431
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumabTotal
American Indian or Alaska Native033
Asian164157
Black or African American235376
Native Hawaiian or Other Pacific Islander011
White249478727
Other132639
Mixed Race202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumabTotal
Hispanic/Latino173350
Not Hispanic/Latino286569855
Background Therapy
Background Therapy(participants)PlaceboEvolocumabTotal
Diet Only3874112
Diet + Atorvastatin 10 mg129256385
Diet + Atorvastatin 80 mg73146219
Diet + Atorvastatin 80 mg + Ezetimibe 10 mg63126189
Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)PlaceboEvolocumabTotal
Mean104.0 ± 21.6104.2 ± 22.1104.1 ± 22.0
Total Cholesterol
Total Cholesterol(mg/dL)PlaceboEvolocumabTotal
Mean179.1 ± 27.2176.8 ± 27.5177.6 ± 27.4
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration(mg/dL)PlaceboEvolocumabTotal
Mean125.6 ± 26.9124.2 ± 25.6124.6 ± 26.1

7 further baseline measures are reported on the registry.

08

Study locations

96 sites
  • Research Site
    Birmingham, Alabama 35216, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Spring Valley, California 91978, United States
  • Research Site
    Westlake Village, California 91361, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Chicago, Illinois 60610, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Louisville, Kentucky 40213, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Chevy Chase, Maryland 20815, United States
  • Research Site
    Columbia, Maryland 21045, United States
  • Research Site
    Brockton, Massachusetts 02301, United States
  • Research Site
    Saint Paul, Minnesota 55114, United States
  • Research Site
    Olive Branch, Mississippi 38654, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Endwell, New York 13760, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Akron, Ohio 44311, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Richmond, Virginia 23294, United States
  • Research Site
    Renton, Washington 98057, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Camperdown, New South Wales 2015, Australia
  • Research Site
    Maroubra, New South Wales 2035, Australia
  • Research Site
    Carina Heights, Queensland 4152, Australia
  • Research Site
    Milton, Queensland 4064, Australia
  • Research Site
    Fitzroy, Victoria 3065, Australia
  • Research Site
    Perth, Western Australia 6000, Australia
  • Research Site
    Feldkirch, 6807, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Anthée, 5520, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Gozee, 6534, Belgium
  • Research Site
    Ham, 3945, Belgium
  • Research Site
    Oostende, 8400, Belgium
  • Research Site
    Victoria, British Columbia V8T 5G4, Canada
  • Research Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Research Site
    Sudbury, Ontario P3C 5K7, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Toronto, Ontario M9W 4L6, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Research Site
    Quebec, G1V 4M6, Canada
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Chomutov, 430 02, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 2, 120 00, Czechia
  • Research Site
    Praha 4, 140 21, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Slany, 274 01, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Baja, 6500, Hungary
  • Research Site
    Budapest, 1085, Hungary
  • Research Site
    Budapest, 1115, Hungary
  • Research Site
    Budapest, 1125, Hungary
  • Research Site
    Komarom, 2991, Hungary
  • Research Site
    Pecs, 7624, Hungary
  • Research Site
    Szeged, 6720, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Lyttelton, Gauteng 0140, South Africa
  • Research Site
    Amanzimtoti, KwaZulu-Natal 4126, South Africa
  • Research Site
    Chatsworth, Durban, KwaZulu-Natal 4092, South Africa
  • Research Site
    Observatory, Western Cape 7925, South Africa
  • Research Site
    Paarl, Western Cape 7646, South Africa
  • Research Site
    Parow, Western Cape 7505, South Africa
  • Research Site
    Somerset West, Western Cape 7130, South Africa
  • Research Site
    Bloemfontein, 9301, South Africa
09

References and documents

Publications

  • Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of Evolocumab on Lipoprotein Particles. Am J Cardiol. 2018 Feb 1;121(3):308-314. doi: 10.1016/j.amjcard.2017.10.028. Epub 2017 Nov 8. PubMed 29221604 ↗
  • Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 Jan;19(1):98-107. doi: 10.1111/dom.12788. Epub 2016 Oct 14. PubMed 27619750 ↗
  • Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. Circ Res. 2015 Sep 25;117(8):731-41. doi: 10.1161/CIRCRESAHA.115.307071. Epub 2015 Jul 30. PubMed 26228031 ↗
  • Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29. PubMed 24678979 ↗
  • Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16. PubMed 33325247 ↗
  • Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7. PubMed 29736889 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31. PubMed 28844508 ↗
  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. PubMed 32114889 ↗
  • Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16. PubMed 29768954 ↗
  • Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug;16(4):538-543. doi: 10.1016/j.jacl.2022.05.069. Epub 2022 Jun 6. PubMed 35760720 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Oct 2013, 21 months.

Results were first posted in Sep 2015, 1 year 11 months after primary completion. A results delay was requested in May 2014.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Jan 25, 2012
StartActual
Jan 5, 2012
Primary completionActual
Oct 14, 2013
CompletionActual
Oct 14, 2013
Results delay requested
May 15, 2014
Results first posted
Sep 29, 2015
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01516879
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Jan 5, 2012
Primary completion
Oct 14, 2013
Completion
Oct 14, 2013
Results posted
Sep 29, 2015
Last update
Jul 22, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion